{"brief_title": "Phase III Randomized, Double-Blind, Placebo-Controlled Study of Mexiletine for Painful Diabetic Neuropathy", "brief_summary": "OBJECTIVES: I. Assess the efficacy and toxicity of mexiletine in the management of paresthesias and pain in patients with diabetic neuropathy.", "detailed_description": "PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are stratified by participating institution. The first group receives oral mexiletine 3 times a day for 6 weeks. The dose is increased after the first week if there are no side effects. The second group receives a placebo. Patients cross to the alternate treatment after a 1-week washout.", "condition": "Paresthesia", "intervention_type": "Drug", "intervention_name": "mexiletine", "criteria": "Patients with painful diabetic neuropathy", "gender": "All", "minimum_age": "21 Years", "maximum_age": "60 Years", "healthy_volunteers": "No", "id": "NCT00004647.xml"}